

Making Evidence-based Decisions Using Alzheimer Therapy (MEDUSA Therapy)

Submission date 30/09/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 30/09/2004	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 18/04/2016	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Roger Bullock

Contact details
Kingshill Research Centre
Victoria Hospital
Okus Road
Swindon
United Kingdom
SN1 4HZ
+44 (0)1793 481182
roger.bullock@kingshill-research.org

Additional identifiers

Protocol serial number
N0038133699

Study information

Scientific Title
Making Evidence-based Decisions Using Alzheimer Therapy (MEDUSA Therapy)

Study objectives

What evidence is there that altering therapy, after initial treatment starts to fail, will benefit the patient?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Alzheimer's disease

Interventions

Randomised controlled trial (RCT):

1. Cholinesterase inhibitor (ChEi) as usual
2. Increased dose of ChEi
3. Rivastigmine
4. Memantine
5. ChEi as usual, plus memantine

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Cholinesterase inhibitor, rivastigmine, memantine

Primary outcome(s)

1. Clinical Global Impression of Change (CGI/C)
2. Mini-Mental State Examination (MMSE)
3. BAYER-Activities of Daily Living (ADL)
4. Neuropsychiatric inventory questionnaire (NPI-Q)
5. Global Assessment Scale (GAS)

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/12/2004

Eligibility

Key inclusion criteria

75 participants (i.e. 15 in each arm of the trial) with diagnosis of Alzheimer's disease (AD) and aged between 55 and 95

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

All

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

30/09/2003

Date of final enrolment

01/12/2004

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Victoria Hospital

Swindon

United Kingdom

SN1 4HZ

Sponsor information

Organisation

Department of Health

Funder(s)

Funder type
Government

Funder Name
Avon and Wiltshire Mental Health Partnership NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration